Emergent BioSolutions Inc... (EBS)
NYSE: EBS
· Real-Time Price · USD
9.24
-0.08 (-0.86%)
At close: Aug 22, 2025, 3:59 PM
9.33
0.92%
After-hours: Aug 22, 2025, 06:52 PM EDT
-0.86% (1D)
| Bid | 9.2 |
| Market Cap | 493.23M |
| Revenue (ttm) | 846.2M |
| Net Income (ttm) | 139.5M |
| EPS (ttm) | 2.62 |
| PE Ratio (ttm) | 3.53 |
| Forward PE | 9.63 |
| Analyst | Buy |
| Ask | 9.65 |
| Volume | 1,131,212 |
| Avg. Volume (20D) | 1,339,998.5 |
| Open | 9.45 |
| Previous Close | 9.32 |
| Day's Range | 9.23 - 9.66 |
| 52-Week Range | 4.02 - 12.73 |
| Beta | 1.98 |
Analyst Forecast
According to 0 analyst ratings, the average rating for EBS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Emergent BioSolutions Inc. is scheduled to release its earnings on
Nov 5, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
+36.65%
Emergent BioSolutions shares are trading higher af...
Unlock content with
Pro Subscription
2 weeks ago
-1.15%
Emergent BioSolutions shares are trading higher after the company reported better-than-expected Q2 financial results.
2 months ago · seekingalpha.com
Emergent BioSolutions: Strategic Turnaround Proving Tricky, But I'm Still HopefulEmergent stock is down >40% since my last update. I had given the stock a "Buy" rating but noted that 2025 may be a difficult year. Emergent's MCM business has performed well, but Narcan sales fell dr...
